Assessing the Value of a New Pharmaceutical: A Feasibility Study of Contingent Valuation in Managed Care

Medical Care

Volumn 36, Issue 3, 1998, Pages 370-384

  O'Brien, Bernie J ^a,b   Goeree, Ron ^a,b   Gafni, Amiram ^a   Torrance, George W ^a,b   Pauly, Mark V ^c   Erder, Haim ^d   Rusthoven, Jim ^a   Weeks, Jane ^e   Cahill, Melissa ^f   Lamont, Bruce ^f  

^a MCMASTER UNIVERSITY   (Canada)

^b ST JOSEPH S HOSPITAL   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d AMGEN INC   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f Dana Farber Cancer Institute ^*

Author keywords

Chemotherapy; Contingent valuation; Willingness to pay

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ALGORITHM; ANALYSIS OF VARIANCE; ARTICLE; ATTITUDE TO HEALTH; COMPARATIVE STUDY; ECONOMICS; FEASIBILITY STUDY; FEMALE; FEVER; FINANCIAL MANAGEMENT; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MALE; NEUTROPENIA; PATIENT ATTITUDE; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; RISK; STATISTICS; UNITED STATES;

ADULT; ALGORITHMS; ANALYSIS OF VARIANCE; ATTITUDE TO HEALTH; FEASIBILITY STUDIES; FEMALE; FEVER; FILGRASTIM; FINANCING, PERSONAL; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; MALE; NEUTROPENIA; PATIENT ACCEPTANCE OF HEALTH CARE; PENNSYLVANIA; QUESTIONNAIRES; RISK;

EID: 0032011179     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005650-199803000-00013     Document Type: Article

References (42)

1. Elixhauser A, Luce BR, Taylor WR, et al. Health Care CBA/CEA: An update in the growth and composition of the literature. Med Care 1993;31:js1.
2. Commonwealth Department of Human Services and Health. Guidelines for the pharmaceutical industry on preparation of submissions to the pharmaceutical benefits advisory committee (including major submissions involving economic analyses), Canberra, Australia, Australian Government Publishing Service; 1995:1.
3. Detsky A. Guidelines for preparation of economic analysis of pharmaceutical products: A draft document for Ontario and Canada. Pharmacoeconomics 1993;3:354.
4. Torrance GW, Blaker D, Detsky A, et al. Canadian Guidelines for the economic evaluation of pharmaceuticals. Pharmacoeconomics 1996;9:535.
5. Adams ME, McCall NT, Gray DT, Orza MJ, Chalmers TC. Economic analysis in randomized control trials. Med Care 1992;30:231.
6. Phelps CE, Mushlin A. On the (near) equivalence of cost-effectiveness and cost-benefit analyses. Int J Technol Assess Health Care 1991;7:12.
7. Doubilet P, Weinstein MC, McNeil BJ. Use and misuse of the term "cost-effective" in medicine. N Engl J Med 1986;314:253.
8. Mason J, Drummond MF, Torrance GW. Some guidelines on the use of cost-effectiveness league tables. Br Med J 1993;306:570.
9. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418.
10. Pauly MV. Valuing health care benefits in money terms. In: Sloan FA, ed. Valuing health care. Cambridge: Cambridge University Press, 1995.
11. Mishan EJ. Cost-benefit analysis. London: Alien and Unwin, 1971.
12. Viscusi WK. Labor market valuations and life and limb: Empirical estimates and policy implications. Public Policy 1978;26:359.
13. Marin A, Psacharopoulos G. The reward for risk in the labor market: Evidence from the United Kingdom and a reconciliation with other studies. J Political Economy 1982;90:827.
14. Jones-Lee MW. The value of a life: An economic analysis. Chicago: University of Chicago Press, 1976.
15. Mishan EJ. Evaluation of life and limb: A theoretical approach. J Political Economy 1971;79:687.
16. Johannesson M, Jonsson B. Economic evaluation in health care: Is there a role for cost-benefit analysis. Health Policy 1991;17:1.
17. Mitchell RC, Carson RT. Using surveys to value public goods: The contingent valuation method. Washington, DC: Resources for the Future, 1989.
18. Thompson MS. Willingness-to-pay and accepts risks to cure chronic disease. Am J Public Health 1986;76:392.
19. Thompson MS, Read JL, Liang M. Feasibility of willingness-to-pay measurement in chronic arthritis. Med Decis Making 1984;4:195.
20. Appel LJ, Steinberg EP, Powe NR, Anderson GF, Dwyer SA, Faden RR. Risk reduction from low osmolality contrast media. What do patients think it is worth? Med Care 1990;28:324.
21. O'Brien B, Gafni A. When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care. Med Decis Making 1996;16:288.
22. Gafni A. Using willingness-to-pay as a measure of benefits: What is the relevant question to ask in the context of public decision making? Med Care 1991;29:1246.
23. Neumann P, Johannesson M. The willingness-to-pay for in vitro fertilization: A pilot study using contingent valuation. Med Care 1994;32:686.
24. National Oceanic and Atmospheric Administration. Natural resource damage assessments under the oil pollution act of 1990. Notice of proposed rules. Federal Register 1993;58:4612.
25. Morstyn G, Campbell L, Souza LM, et al. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 1988;1:667.
26. Bronchud MH, Scarffe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987;56:809.
27. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991;315:164.
28. Lyman GH, Lyman CG, Sanderson RA, Balducci L. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 1993;85:488.
29. Nichols CR, Fox EP, Roth BJ, et al. Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 1994;12:1245.
30. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 1996;12:2471.
31. American Society of Clinical Oncology. Updated recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 1996;14:1957.
32. Levine MN, Gafni A, Markham B, MacFarlane D. A bedside decision instrument to elicit a patient's preference concerning adjunct chemotherapy for breast cancer. Ann Intern Med 1992;117:53.
33. Whelan TJ, Levine MN, Gafni A, et al. Breast implantation post lumpectomy: Development and evaluation of a decision instrument. J Clin Oncol 1995;13:847.
34. Sebban C, Browman G, Gafni A, et al. Design and validation of a bedside decision instrument to elicit a patient's preferences concerning allogenic bone marrow transplantation in chronic myeloid leukemia. Am J Hematol 1995;48:221.
35. Elit LM, Levine MN, Gafni A, et al. Patients' preferences for therapy in advanced epithelial ovarian cancer: Development, testing, and application of a bedside decision instrument. Gynecol Oncol 1996;62:329.
36. O'Brien B, Novosel S, Torrance GW, Streiner D. Assessing the economic value of a new antidepressant: A willingness-to-pay approach. Pharmacoeconomics 1995;8:34.
37. Stalhammar NO. An empirical note on willingness to pay and starting point bias. Med Decis Making 1996;16:242.
38. O'Brien B, Viramontes JL. Willingness to pay: A valid and reliable measure of health state preference? Med Decis Making 1994;14:289.
39. Slovic P. Perception of risk. Science 1987;236:280.
40. Jones-Lee MW, Hammerton M, Phillips PR. The value of safety: Results of a National survey. Economic J 1985;95:49.
41. Kahneman D, Tversky A. Prospect theory: An analysis of decision under risk. Econometrica 1979;47:263.
42. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996.